A study found that patients with multiple myeloma had dramatically worse outcomes in real-world settings than in clinical trials. Patients in the real-world experienced worse progression-free and overall survival on six of seven standard treatments compared with those in clinical trials. The analysis included nearly 4000 patients with multiple myeloma and compared real-world outcomes with patient outcomes reported in randomized controlled trials. Patients in clinical trials are healthier and overcome logistical challenges, resulting in better outcomes. This may necessitate a change in the way health care professionals speak to patients about potential outcomes. It remains unclear how effective multiple myeloma drugs are outside of the clinical trial setting. The study was presented at the annual meeting of the American Society of Hematology. No funding was reported.
Source link
In Real World, Patients With Myeloma Have Worse Outcomes
